CCR3 and neoplasm: The combined use of IL‐1R and CCR3 inhibitors significantly suppressed tumor progression in liver metastasis (Figure S3C, Supporting Information), liver weight (Figure S3D, Supporting Information), and the estimated metastasis site (Figure S3E, Supporting Information), and improved OS (Figure S3F, Supporting Information).